Diagnostic features described in the disease definition include the characteristic histological pattern of neoplastic cells with rounded homogeneous nuclei and clear cytoplasm in a honeycomb arrangement. No additional certified diagnostic criteria are documented in this packet.

No certified approved treatments or orphan-designated therapies for oligodendroglioma are documented in this packet. Clinical research is evaluating targeted IDH inhibition: a Phase 3 study of safusidenib in grade 2 IDH1-mutant glioma (NCT07712757, Nuvation Bio, expected to begin 2027) and a Phase 2 study evaluating proton beam or IMRT in IDH mutant grade II–III glioma (NCT03180502, NRG Oncology) are among the active trials.

Prognosis is not certified in this packet.

The research landscape includes 189 classified articles, with diagnostic and biomarker research as the dominant publication type. Active trials include a Phase 2 study of safusidenib for patients whose disease progressed on vorasidenib (NCT07703436, Nuvation Bio), and a Phase 2 examination of chemotherapy and radiation in IDH-mutant grade II–III glioma (NCT03180502, NRG Oncology). The published literature reflects active biomarker and molecular characterization work.